Bioequivalence Study Of Pediatric Appropriate Formulation

An Open Label, Randomized, Single Dose, Two-Way Crossover Bioequivalence Study Comparing A New 80 Mg (2x40 mg) Pediatric Appropriate Formulation To A 80 Mg Commercial Atorvastatin Calcium Tablet Formulation In Healthy Subjects

To determine bioequivalence of pediatric appropriate 80 mg atorvastatin formulation comparing to the 80 mg commercial atorvastatin calcium tablet formulation.

Determination of Bioequivalence

Inclusion Criteria:

• Healthy male and/or female volunteers
• Mass Index (BMI) of approximately 18 to 30 kg/m2

Exclusion Criteria:

• Any condition possibly affecting drug absorption
• A positive urine drug screening